Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/123929
Title: Contribution Of Human Papillomavirus In Neuroendocrine Tumors From A Series Of 10,575 Invasive Cervical Cancer Cases
Author: Alejo, Maria
Alemany i Vilches, Laia
Clavero, Omar
Quirós, Beatriz
Vighi, Susana
Seoud, Muhieddine
Cheng-Yang, Chou
Garland, Suzanne M.
Juanpere, Nuria
Lloreta Trull, Josep
Tous, Sara
Klaustermeier, Jo Ellen
Quint, Wim
Bosch José, Francesc Xavier, 1947-
Sanjosé Llongueras, Silvia de
Lloveras Rubio, Betlem
RIS HPV TT study group
Keywords: Papil·lomavirus
Tumors
Neuroendocrinologia
Papillomaviruses
Papillomaviruses
Tumors
Neuroendocrinology
Issue Date: 1-Jun-2018
Publisher: Elsevier Science Bv
Abstract: Aims: Neuroendocrine tumors (NET) of the cervix are rare tumors with a very aggressive course. The human papillomavirus (HPV) has been linked to its etiology. The objective of this study is to describe HPV prevalence and genotype distribution of NET. Methods and Results: Forty-nine tumors with histological neuroendocrine features were identified among 10,575 invasive cervical cancer (ICC) cases from an international study. HPV DNA detection was done using SPF10/DEIA /LiPA(25) system. Immunohistochemical (IHC) staining for neuroendocrine markers (chromogranin A, synaptophysin, CD56) and for p16(INK4a) as a surrogate for HPV transforming infection was performed. In 13 samples with negative IHC for all 3 neuroendocrine markers studied, it was possible to conduct electron microscopy (EM). NET represented 0.5% of the total ICC series and HPV was detected in 42 out of 49 samples (85.7%, 95% CI: 72.8%, 94.1%). HPV16 was the predominant type (54.8%), followed by HPV18 (40.5%). p16(INK4a) overexpression was observed in 38/44 cases (86.4%). Neuroendocrine IHC markers could be demonstrated in 24/37 (64.9%) cases. EM identified neuroendocrine granules in 8 samples with negative IHC markers. Conclusions: Our data confirms the association of cervical NET with HPV and p16(INK4a) overexpression. Specifically, HPV16 and 18 accounted together for over 95% of the HPV positive cases. Current HPV vaccines could largely prevent these aggressive tumors.
Note: Reproducció del document publicat a: https://doi.org/10.1016/j.pvr.2018.03.005
It is part of: Papillomavirus Research, 2018, Vol. 5, p. 134-142
URI: http://hdl.handle.net/2445/123929
Related resource: https://doi.org/10.1016/j.pvr.2018.03.005
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
AlejoM.pdf2.84 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons